Anti-Amyloid Therapies and the Danger of ARIA

A new class of drugs called anti-amyloid therapies (such as lecanemab and donanemab) has recently been approved to treat early Alzheimer’s disease ^[1][2]. While these drugs offer hope for some, they pose a unique and potentially life-threatening risk for people with APP-related amyloidosis and Cerebral Amyloid Angiopathy (CAA) ^[3][4].

What Are Anti-Amyloid Therapies?

These medications are monoclonal antibodies designed to find and remove amyloid plaques from the brain ^[5]. While they can be effective at clearing plaques from the brain tissue, they do not distinguish between amyloid in the tissue and amyloid that has built up in your blood vessel walls ^[3][6].

The Danger: What is ARIA?

The most significant side effect of these drugs is a condition called ARIA (Amyloid-Related Imaging Abnormalities) ^[7]. ARIA occurs when the antibodies interact with the amyloid in your brain, causing the blood vessels to leak or become inflamed. There are two types:

• ARIA-E (Edema): This is swelling or fluid buildup in the brain tissue ^[8].
• ARIA-H (Hemorrhage): This refers to bleeding in the brain, including new microbleeds, superficial staining (siderosis), or larger, more dangerous bleeds ^[9][10].

In clinical trials for early Alzheimer’s, ARIA-E occurred in about 13% to 24% of participants ^[1][2]. While many cases are “asymptomatic” (found only on an MRI), others can cause headaches, worsening confusion, dizziness, seizures, or even death ^[8][11].

Why Your Condition Increases the Risk

The clinical trials for these drugs were very careful about who they allowed to participate. They specifically excluded most people who had signs of significant CAA, such as having more than four microbleeds on their MRI ^[12][13].

For someone with an APP mutation, the risk is much higher because:

1. Vessel Vulnerability: Your blood vessels are already fragile and “overloaded” with amyloid ^[3].
2. Antibody Interaction: The drugs may “destabilize” your blood vessel walls as they try to pull the amyloid out, leading to immediate leaks or major hemorrhages ^[3][4].
3. Fatal Bleeding: Serious and fatal brain bleeds have been reported in patients taking these drugs, particularly those who were also on blood thinners or received “clot-busting” drugs in the ER ^[10][14].

Because of these risks, many experts consider significant CAA or APP-related vascular disease an appropriate-use exclusion—meaning the treatment is generally considered unusually hazardous ^[12][13]. It’s important to note that patients with severe CAA were largely excluded from clinical trials, so safety data for this specific community is very limited.

The Role of the APOE4 Gene

Another gene, called APOE, can further complicate your risk. Most people have two copies of this gene. If you have the APOE4 variant, your risk for ARIA increases significantly ^[15].

• One Copy (Heterozygote): Increases the risk of brain swelling (ARIA-E) by about double compared to non-carriers ^[15].
• Two Copies (Homozygote): Increases the risk dramatically; for example, in lecanemab trials, 34.5% of people with two copies of APOE4 experienced brain swelling ^[10].

Doctors now often recommend APOE genotyping (a blood test) for anyone considering these treatments to help understand their personal risk level ^[13][12].

Advocacy and Decision Making

If you are offered an anti-amyloid therapy, it is critical to advocate for yourself. Ensure your doctor has reviewed your most recent “blood-sensitive” MRI (GRE or SWI sequences) and is aware of your APP status ^[16]. If you are on these therapies, do not categorically refuse acute stroke care (like tPA) yourself, but ensure the ER team knows you are on the drug so they can review your MRI and assess the risks.

The decision to start these drugs involves a difficult “trade-off”: a statistically modest slowing of memory loss versus a real and serious risk of brain swelling or a major bleed ^[5][3]. For those with hereditary vascular amyloidosis, the safety data is still very limited, and extreme caution is the standard recommendation ^[16].